<< Back to News

System Formulary Update
Botulinum Neurotoxins Type A and B

Situation

The botulinum neurotoxins type A and B class review and formulary standardization was approved at the November 2021 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), onabotulinumtoxinA (Botox), rimabotulinumtoxinB (Myobloc)

Assessment/Recommendation

Changes effective: Tuesday January 11, 2022

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Dysport Vial: 300 units, 500 units (preferred; available inpatient and outpatient)
• Botox Vial: 100 units – restricted to outpatient encounter/clinic use only
• Xeomin Vial: 50 units, 100 units – restricted to outpatient encounter/clinic use only
• Myobloc Vial: 5,000 units/mL (1 mL) – restricted to outpatient encounter/clinic use only

Note: Stock of these formulary products may vary at individual entities

As a result, the following products will be removed from the UNC Health Medication Formulary

• Not applicable